China Pharmaceutical: Revenue of non-epidemic related product sales decreased by 9% in the first quarter
On April 29, China Pharmaceutical continued to close and closed continuously, always reported at 14.16 yuan / share, a drop of 2.twenty one%.In the news, China Pharmaceutical disclosed the report of the first quarter of 2020 yesterday that the demand for non-epidemic drugs and medical materials declined due to the impact of the new coronary pneumonia epidemic. The company’s non-epidemic related product sales scale has improved, and operating income in the first quarter of 2020 was 74.8.5 billion, and its operating income in the first quarter of 2019 was 82.4.5 billion US dollars, the company’s overall revenue fell by 9 year-on-year.21%, the net profit attributable to shareholders of listed companies fell by 35% year-on-year.49%.In addition, China Pharmaceutical said in its recently disclosed 2019 annual report that due to the influence of policy factors such as “purchasing with volume” and “restriction of resistance”, some products have not been sold well.During the reporting period, the company’s operating income was 352.85 ppm, an increase of 13 in ten years.8%; net profit attributable to shareholders of listed companies9.81 ppm, a decrease of 36 per year.46%.Sauna, Ye Wang Li Yunqi Editor Yue Caizhou Proofreading Liu Baoqing

Author